Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.

ABSTRACT:

Background

OnabotulinumtoxinA is effective in treating chronic migraine (CM), but there are limited data assessing how allodynia affects preventive treatment responses. This subanalysis of the 108-week, multicenter, open-label COMPEL Study assessed the efficacy and safety of onabotulinumtoxinA in people with CM with and without allodynia.

Methods

Patients (n = 715) were treated with onabotulinumtoxinA 155 U every 12 weeks for 9 treatment cycles. The Allodynia Symptom Checklist was used to identify patients with allodynia (scores ≥3). The primary outcome for this subanalysis was reduction in monthly headache days from baseline for weeks 105 to 108 in groups with and without allodynia. Other outcomes included assessments of moderate to severe headache days, disability (using t

SUBMITTER: Young WB 

PROVIDER: S-EPMC6734222 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature